Sanofi-a Ventis Deutschland Gmbh

Aventis Pharma Deutschland, Gmbh

Ekkehard Leberer

Thomas Leeuw

Eckart Bartnik

Joerg Czech

Andreas R Klatt

Sebastian Barradeau

Edmund Hoppe

Luc Mercken

Gisela Peraus

Jonathan Rothblatt

Detlef Kozian

Ursula Mangold

Almut Nitsche

Pauline Fraissignes

Sabine Gratzer

Allegra Ritscher

Sylvie Dreisler

Bert Klebl

Rosemarie Söllner

Anja Stadler

The invention refers to the use of a p21-activated kinase (PAK) inhibitor as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.

Use of PAK inhibitor for the treatment of a joint disease

The present invention relates to an improved process for determining &#x3b3;-secretase activity and for detecting &#x3b3;-secretase, a subunit protein of &#x3b3;-secretase, or a &#x3b3;-secretase-like proteinase. In particular, the present invention relates to processes for the identification of a &#x3b3;-secretase or of a cDNA which codes for a &#x3b3;-secretase, a subunit protein of &#x3b3;-secretase, or a &#x3b3;-secretase-like proteinase. Another embodiment of the present invention relates to processes for the identification of substances which can inhibit the activity of &#x3b3;-secretase, or a &#x3b3;-secretase-like proteinase.

Method of screening for gamma-secretase activity

The present invention relates to a method for determining the activity of ornithine decarboxylase and for identifying effectors of ornithine decarboxylase activity, to the effectors of ornithine decarboxylase activity, and to the use thereof as pharmaceuticals for the treatment of disorders of the polyamine level.

Method for determining the activity of ornithine decarboxylase and for identifying effectors of ornithine decarboxylase activity

The invention relates to processes for identifying inhibitors and activators of eukaryotic potassium channels, in which a mutatedcell is used whose endogenous potassium channels TRK1, TRK2 and TOK1 are not expressed functionally, but which expresses heterologously a eukaryotic potassium channel to be studied. Other subject matters of the invention are mutatedcells which do not express TRK1, TRK2 and TOK1, and the preparation and use of these mutatedcells.

[object Object]

The invention refers to the use of a p21-activated kinase (PAK) inhibitor for the treatment of a joint disease such as osteoarthritis or rheumatoid arthritis or for the treatment of a joint pain and the use of PAK as a target protein for the discovery of a PAK inhibitor as a medicament for the treatment of a joint disease.

The present invention relates to a promoter, to DNA fragments containing said promoter and to the use thereof, in particular in methods for identifying substances exhibiting an activating or inhibiting action on G protein-coupled receptors.

Promotor for functional characterization of G-protein coupled receptors in the yeast saccharomyces cerevisiae

Growing community of inventors

Germering, Germany

Ekkehard Leberer